Access to Treatment

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Unsettled rules, pending FDA decisions, insurer responses and state opt-ins signal a staggered 2026 rollout.